23andMe sent an email to developers saying it will disable its API in two weeks; apps will only be able to use the company's generated reports, not the raw data
23andMe, which provides DNA testing kids for consumers, is telling outside app developers that they'll no longer have access to the company's raw genomic data.
Context & Ripple Effects
In 2018, 23andMe began closing what had been an unusually open door: outside developers could pull customers' raw genomic files through its API. This notice gives apps two weeks before they are limited to the company's own generated reports. It is an early move in a pattern of tightening control — years later the company rewrote its terms of service to block lawsuits right after a major data breach, and by 2025 it filed for bankruptcy with its genetic database as the core asset being sold.
First-order effects
- Third-party app developers lose raw-genomic-data access in two weeks and must either rebuild on 23andMe's curated reports or abandon their integrations.
- Customers who used outside apps to analyze their own DNA lose that option unless they downloaded their raw files directly.
Second-order effects
- With the API closed, 23andMe becomes the sole gatekeeper of interpretation on top of its dataset, strengthening its position just as the broader DNA-testing category slows — Ancestry's layoffs cited most early adopters having already enrolled.
- A shrinking third-party ecosystem removes independent scrutiny of how the raw data is handled, a gap that became consequential when the 2023 breach exposed millions of accounts.
Third-order effects
- Consumer genomics platforms are converging on treating raw genetic databases as proprietary balance-sheet assets rather than open infrastructure — a trajectory that ends with regulators and officials warning during the bankruptcy that customer genetic data could be sold or exposed.
- If platforms keep locking down data access while retaining liability for breaches, expect pressure for rules governing who controls and can transfer consumer genomic data when a company fails.
The trend: Consumer DNA companies are shifting from open-API ecosystems toward closed, proprietary control of genomic databases — control that ultimately made the database itself the asset in a bankruptcy sale.